National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (1)
- Adverse Events (1)
- Anxiety (1)
- Behavioral Health (10)
- Care Management (1)
- Comparative Effectiveness (2)
- (-) Depression (11)
- Elderly (1)
- Evidence-Based Practice (1)
- Human Immunodeficiency Virus (HIV) (3)
- (-) Medication (11)
- Medication: Safety (1)
- Opioids (1)
- Outcomes (1)
- Pain (1)
- Patient-Centered Outcomes Research (3)
- Patient Adherence/Compliance (3)
- Patient Safety (1)
- Practice Patterns (1)
- Racial and Ethnic Minorities (1)
- Respiratory Conditions (1)
- Social Stigma (2)
- Substance Abuse (1)
- Surgery (1)
- Tobacco Use (1)
- Vulnerable Populations (1)
- Women (1)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 11 of 11 Research Studies DisplayedSakurai H, Dording C, Yeung A
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.
While riluzole has been investigated for the treatment of depression, little is known about its longer-term efficacy and optimal treatment duration in treatment-resistant depression (TRD). The objective of this study was to characterize the longer-term outcome of adjunctive riluzole therapy for TRD in an open-label extension of an 8-week acute treatment trial. The investigators concluded that longer-term adjunctive riluzole appeared relatively well tolerated and beneficial for maintaining previous response.
AHRQ-funded; HS023000.
Citation: Sakurai H, Dording C, Yeung A .
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression.
J Affect Disord 2019 Nov 1;258:102-08. doi: 10.1016/j.jad.2019.06.065..
Keywords: Depression, Behavioral Health, Medication, Patient-Centered Outcomes Research, Outcomes
Wilkinson ST, Howard DH, Busch SH
Psychiatric practice patterns and barriers to the adoption of esketamine.
This paper discusses the psychiatric practice patterns and barriers to the adoption of esketamine in the treatment of depression. The authors indicate that the discovery of ketamine’s rapid-acting properties, culminating most recently with the FDA’s approval of esketamine, offers hope to the large numbers of patients whose symptoms do not resolve with traditional treatments. However, they suggest, many traditional psychiatric practices may be reluctant to invest in the costly infrastructure necessary to provide this therapy, especially because of the uncertainty regarding the reimbursement for patient monitoring.
AHRQ-funded; HS023000.
Citation: Wilkinson ST, Howard DH, Busch SH .
Psychiatric practice patterns and barriers to the adoption of esketamine.
JAMA 2019 Sep 17;322(11):1039-40. doi: 10.1001/jama.2019.10728.
.
.
Keywords: Depression, Behavioral Health, Practice Patterns, Medication
Sobieraj DM, Martinez BK, Hernandez AV
Adverse effects of pharmacologic treatments of major depression in older adults.
The objective of this study was to assess adverse effects of pharmacologic antidepressants for treatment of major depressive disorder (MDD) in adults 65 years of age or older. The investigators found, among other conclusions, that in patients 65 years of age or older with MDD, treatment of the acute phase of MDD with serotonin norepinephrine reuptake inhibitors (SNRIs), but not selective serotonin reuptake inhibitors (SSRIs), was associated with a statistically greater number of overall adverse events vs placebo.
AHRQ-funded; 290201500012I.
Citation: Sobieraj DM, Martinez BK, Hernandez AV .
Adverse effects of pharmacologic treatments of major depression in older adults.
J Am Geriatr Soc 2019 Aug;67(8):1571-81. doi: 10.1111/jgs.15966..
Keywords: Depression, Behavioral Health, Medication: Safety, Medication, Adverse Drug Events (ADE), Adverse Events, Patient Safety, Elderly
Hill LM, Golin CE, Gottfredson NC
Drug use mediates the relationship between depressive symptoms and adherence to ART among recently incarcerated people living with HIV.
The purpose of this study was to identify the mechanisms involved with antiretroviral therapy (ART) non-adherence among people living with HIV (PLHIV) after release from prison. Results showed that, on average, study participants achieved 79% ART adherence. Greater symptoms of depression were associated with greater drug use, which was in turn associated with lower adherence. Lower adherence self-efficacy was associated with depressive symptoms, but not with adherence. Results suggested that depression screening and targeted mental health and substance use services for depressed individuals at risk of substance use constitute important steps to promote adherence to ART after prison release.
AHRQ-funded; HS000032.
Citation: Hill LM, Golin CE, Gottfredson NC .
Drug use mediates the relationship between depressive symptoms and adherence to ART among recently incarcerated people living with HIV.
AIDS Behav 2019 Aug;23(8):2037-47. doi: 10.1007/s10461-018-2355-3..
Keywords: Behavioral Health, Depression, Human Immunodeficiency Virus (HIV), Medication, Patient Adherence/Compliance, Substance Abuse, Vulnerable Populations
Lipira L, Williams EC, Huh D
HIV-related stigma and viral suppression among African-American women: exploring the mediating roles of depression and ART nonadherence.
Investigators recruited a sample of African-American women living with HIV to participate in a stigma-reduction intervention. The women lived in Chicago and Birmingham from 2013 to 2015. The relationship between HIV-related stigma and viral suppression was evaluated and the role of depression and nonadherence to antiretroviral therapy (ART) was assessed. Among 100 women who participated 95% reported some level of HIV-related stigma. Those who reported higher levels of stigma did have lower odds of being virally suppressed. The indirect effects of depression and ART nonadherence were not statistically significant.
AHRQ-funded; HS013853.
Citation: Lipira L, Williams EC, Huh D .
HIV-related stigma and viral suppression among African-American women: exploring the mediating roles of depression and ART nonadherence.
AIDS Behav 2019 Aug;23(8):2025-36. doi: 10.1007/s10461-018-2301-4..
Keywords: Depression, Human Immunodeficiency Virus (HIV), Medication, Behavioral Health, Patient Adherence/Compliance, Racial and Ethnic Minorities, Social Stigma, Women
Wilkinson ST, Farmer C, Ballard E
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
The article describes a study on the effectiveness of midazolam as a comparator in preserving the blind in ketamine studies for mood disorders. Four groups -- ketamine (midazolam-controlled), ketamine (saline-controlled), midazolam, and saline -- were compared with regard to clinical outcomes. The effect of ketamine was larger in saline-controlled studies than in midazolam-controlled studies, relative to control, but there was no difference between ketamine (midazolam-controlled) and ketamine (saline-controlled). The response rate for ketamine was higher than the control condition for both saline and midazolam.
AHRQ-funded; HS023000.
Citation: Wilkinson ST, Farmer C, Ballard E .
Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant.
Neuropsychopharmacology 2019 Jun;44(7):1233-38. doi: 10.1038/s41386-019-0317-8.
.
.
Keywords: Medication, Comparative Effectiveness, Depression, Behavioral Health, Patient-Centered Outcomes Research
Turan B, Crockett KB, Buyukcan-Tetik A
Buffering internalization of HIV stigma: implications for treatment adherence and depression.
One mechanism through which social stigma of HIV affects health outcomes for people living with HIV (PLWH) is through internalization of stigma. However, this transformation of social stigma in the community into internalized stigma may not be of the same magnitude for all PLWH. In this study, the investigators examined the moderating effects of 3 personality traits-fear of negative social evaluation, attachment-related anxiety, and dispositional resilience-in transforming perceived stigma in the community into internalized stigma. They also investigated downstream effects of these moderated associations on depressive symptoms and antiretroviral treatment (ART) adherence.
AHRQ-funded; HS013852.
Citation: Turan B, Crockett KB, Buyukcan-Tetik A .
Buffering internalization of HIV stigma: implications for treatment adherence and depression.
J Acquir Immune Defic Syndr 2019 Mar;80(3):284-91. doi: 10.1097/qai.0000000000001915..
Keywords: Depression, Human Immunodeficiency Virus (HIV), Medication, Behavioral Health, Patient Adherence/Compliance, Social Stigma
Iyer AS, Holm KE, Bhatt SP
Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - a cross sectional analysis of the COPDGene cohort.
This study compared the frequency of anxiety/depressive symptoms of current and former smokers with and without COPD and their use of anxiolytic-hypnotics/antidepressants. A cohort of 5331 current/former smokers were surveyed. About 25% of smokers with and without COPD had anxiety/depressive symptoms. Unmedicated smokers tended to be African American, male, have no health insurance, have severe-very severe COPD and higher respiratory symptoms/exacerbation history.
AHRQ-funded; HS023009; HS013852.
Citation: Iyer AS, Holm KE, Bhatt SP .
Symptoms of anxiety and depression and use of anxiolytic-hypnotics and antidepressants in current and former smokers with and without COPD - a cross sectional analysis of the COPDGene cohort.
J Psychosom Res 2019 Mar;118:18-26. doi: 10.1016/j.jpsychores.2019.01.002..
Keywords: Anxiety, Medication, Respiratory Conditions, Depression, Behavioral Health, Anxiety, Tobacco Use
Parthipan A, Banerjee I, Humphreys K
Predicting inadequate postoperative pain management in depressed patients: a machine learning approach.
Researchers employed a machine-learning approach to identify patients who were prescribed a combination of selective serotonin reuptake inhibitors (SSRIs) and prodrug opioids in order to examine the effect of this combination on postoperative pain control. They identified patients who received surgery over a 9-year period by using EHR data from an academic medical center, then developed and validated natural language processing (NLP) algorithms to extract depression-related information from both structured and unstructured data elements. The machine-learning algorithm accurately predicted the increase or decrease of the discharge, 3-week, and 8-week follow-up pain scores when compared to the pre-operative pain score; pre-operative pain, surgery type, and opioid tolerance were the strongest predictors of postoperative pain control. The researchers conclude that their study results provide the first direct clinical evidence that the known ability of SSRIs to inhibit prodrug opioid effectiveness is associated with worse pain control among depressed patients. They suggest that prescribers might choose direct acting opioids such as oxycodone or morphine for depressed patients on SSRIs instead of prodrug opioids.
AHRQ-funded; HS024096.
Citation: Parthipan A, Banerjee I, Humphreys K .
Predicting inadequate postoperative pain management in depressed patients: a machine learning approach.
PLoS One 2019 Feb 6;14(2):e0210575. doi: 10.1371/journal.pone.0210575..
Keywords: Care Management, Depression, Medication, Opioids, Pain, Surgery
Wilkinson ST, Sanacora G
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
This article reviews the developmental progress of compounds, including glutamate-targeting drugs, that act on amino acid neurotransmitter systems as well as their purported mechanisms of action. Evidence suggests that these systems have a central role in the pathophysiology of mood disorders. The results of this review include information on new glutamatergic/GABAergic compounds in development that show promise and may be available as approved clinical treatments in the near future. The authors also express cautious optimism regarding improvements in the antidepressant research pipeline.
AHRQ-funded; HS023000.
Citation: Wilkinson ST, Sanacora G .
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems.
Drug Discov Today 2019 Feb;24(2):606-15. doi: 10.1016/j.drudis.2018.11.007..
Keywords: Medication, Depression, Behavioral Health
Mathew SJ, Wilkinson ST, Altinay M
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: The ELEKT-D study protocol.
This article discusses the protocol that will be used for an ongoing study to compare electroconvulsive therapy (ECT) vs. ketamine for patients with treatment-resistant major depressive disorder (MDD). The study is being called ELEKT-D. Patients will be randomized between thrice-weekly ECT treatments or intravenous ketamine given twice weekly for 3-5 weeks. The objective of the study is to determine if ketamine will retain 90% of the ECT treatment effect. Additional outcomes to be measured include remission rates, depression severity, cognitive functioning, quality of live, adverse events, and tolerability.
AHRQ-funded; HS023000.
Citation: Mathew SJ, Wilkinson ST, Altinay M .
ELEctroconvulsive therapy (ECT) vs. Ketamine in patients with treatment-resistant depression: The ELEKT-D study protocol.
Contemp Clin Trials 2019 Feb;77:19-26. doi: 10.1016/j.cct.2018.12.009..
Keywords: Depression, Behavioral Health, Medication, Comparative Effectiveness, Patient-Centered Outcomes Research, Evidence-Based Practice